Real-World Evidence on Herbal Medicine Prescriptions for Stroke Sequelae in Korean Cohort
This retrospective cohort study utilized nationwide health insurance claims data from Korea to evaluate reimbursed herbal medicine prescriptions. The setting was a nationwide health insurance claims data system. The population consisted of 942 patients diagnosed with sequelae of cerebrovascular disease participating in a pilot program between November 2020 and April 2024. Mean patient age was 73.2 ± 6.0 years.
The intervention involved prescriptions for herbal medicines including Gamidaebo-tang (23.1%), Mangeum-tang (5.8%), and Gagampalmi-hwan (5.1%). Treatment timing data indicated that 57% initiated herbal medicine treatment more than 1 year after stroke onset. There was no external comparator, utilizing a within-subject comparison of first versus last visits. Symptom changes were assessed in 609 patients with paired symptom records. Results showed 19.4% improved, 71.9% stable, and 8.7% worsened.
Safety outcomes were identified from newly added diagnostic codes, but specific adverse event rates were not reported in the abstract. Serious adverse events and discontinuations were not reported. Key limitations include the retrospective analysis design and claims data limitations. The p-value was not reported in the text.
This study aims to generate real-world evidence on safety and effectiveness. However, as an observational study, association cannot be inferred as causation. Clinicians should recognize these findings as preliminary evidence from a national pilot reimbursement program.